SurinameTuberculosis profile
Population  2016 <1 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.011 (0.011–0.012) 2 (1.9–2.1)
Mortality (HIV+TB only) <0.01 (<0.01–0.01) 1.4 (1–1.8)
Incidence  (includes HIV+TB) 0.14 (0.11–0.18) 26 (20–32)
Incidence (HIV+TB only) 0.036 (0.028–0.046) 6.5 (5–8.3)
Incidence (MDR/RR-TB)** 0.011 (<0.01–0.019) 1.9 (0.44–3.4)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.01 (<0.01–0.013) 0.043 (0.032–0.054) 0.053 (0.04–0.067)
Males 0.011 (<0.01–0.014) 0.078 (0.059–0.098) 0.089 (0.067–0.11)
Total 0.022 (0.016–0.027) 0.12 (0.091–0.15) 0.14 (0.11–0.18)
TB case notifications, 2016  
Total cases notified 116
Total new and relapse 114
          - % tested with rapid diagnostics at time of diagnosis 66%
          - % with known HIV status 94%
          - % pulmonary 85%
          - % bacteriologically confirmed among pulmonary 82%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.14 (0.1–0.18)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 25 23%
          - on antiretroviral therapy 14 56%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  6
(0–11)
Estimated % of TB cases with MDR/RR-TB 6.1% (1.7–15) 0% (0–41)  
% notified tested for rifampicin resistance 63% 67% 75
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 4, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 0, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 76% 140
Previously treated cases, excluding relapse, registered in 2015 29% 7
HIV-positive TB cases registered in 2015 58% 36
MDR/RR-TB cases started on second-line treatment in 2014   0
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions) 1.6
Funding source: 25% domestic, 32% international, 43% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-15 Data: www.who.int/tb/data